ÉTUDE•En prescrivant deux médicaments chez des patients atteints d’un cancer de la prostate, des chercheurs américains ont obtenu des résultats très encourageants qui réduisent les risques de décès de ...

The use of alpha-blockers for benign prostatic hyperplasia is tied to an increased risk of developing acute angle-closure glaucoma, a study finds.

A groundbreaking study reveals that combining two drugs significantly boosts survival for men with high-risk, recurring prostate cancer. This dual the ...

Once E3 tags CYP17A1, the cell uses its proteasome to break down the enzyme entirely. One major advantage of PROTACs is that ...

Une étude internationale redonne espoir aux patients atteints d'un cancer de la prostate avec une avancée majeure et inattendue. Pour mener leurs travaux, les scientifiques ont réparti les ...

Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is ...

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by up to 40 per cent. The treatment pairs standard hormone therapy with a ...

The latest treatments for an enlarged prostate may help reduce prostate size or reduce symptoms. Treatments include water vapor thermal therapy, prostatic urethral lift, and prostate artery ...

Prostate cancer can come back, even after you've had treatment and your doctor declared you cancer-free. Prostate cancer that returns after treatment is called recurrent prostate cancer. Prostate ...

GREENVILLE, S.C. (WSPA) – September is Prostate Cancer Awareness Month, and doctors emphasize that early detection can save lives. Despite its prevalence, many misconceptions about the disease persist ...

26/11 Hengrui Medicine obtient l'autorisation d'essai clinique pour une monothérapie contre les tumeurs ; l'action grimpe de 3 % MT 26/11 Hengrui Medicine obtient l'autorisation d'essai clinique pour ...